IOVA Iovance Biotherapeutics Inc

Price (delayed)

$12.79

Market cap

$2.02B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.39

Enterprise value

$1.98B

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy ...

Highlights
The company's quick ratio fell by 39% YoY but it rose by 6% QoQ
Iovance Biotherapeutics's debt has soared by 54% YoY
IOVA's equity is down by 37% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of IOVA
Market
Shares outstanding
157.8M
Market cap
$2.02B
Enterprise value
$1.98B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$376.41M
EBITDA
-$355.35M
Free cash flow
-$296.25M
Per share
EPS
-$2.39
Free cash flow per share
-$1.88
Book value per share
$3.01
Revenue per share
$0
TBVPS
$3.88
Balance sheet
Total assets
$610.88M
Total liabilities
$138.19M
Debt
$80.48M
Equity
$472.69M
Working capital
$367.4M
Liquidity
Debt to equity
0.17
Current ratio
6.72
Quick ratio
6.71
Net debt/EBITDA
0.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51.6%
Return on equity
-64.2%
Return on invested capital
-58.7%
Return on capital employed
-68.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IOVA stock price

How has the Iovance Biotherapeutics stock price performed over time
Intraday
-1.99%
1 week
3.31%
1 month
-0.08%
1 year
-39.64%
YTD
-33%
QTD
15.85%

Financial performance

How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$377.15M
Net income
-$376.41M
Gross margin
N/A
Net margin
N/A
Iovance Biotherapeutics's net income has decreased by 33% YoY and by 5% QoQ
The company's operating income fell by 33% YoY and by 5% QoQ

Growth

What is Iovance Biotherapeutics's growth rate over time

Valuation

What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
4.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 25% YoY and by 4.4% from the previous quarter
IOVA's equity is down by 37% year-on-year and by 14% since the previous quarter
IOVA's price to book (P/B) is 29% less than its 5-year quarterly average of 6.0 and 10% less than its last 4 quarters average of 4.7

Efficiency

How efficient is Iovance Biotherapeutics business performance
The ROE has dropped by 56% year-on-year and by 17% since the previous quarter
The return on assets has declined by 43% year-on-year and by 14% since the previous quarter
Iovance Biotherapeutics's ROIC has decreased by 40% YoY and by 15% from the previous quarter

Dividends

What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IOVA.

Financial health

How did Iovance Biotherapeutics financials performed over time
The company's quick ratio fell by 39% YoY but it rose by 6% QoQ
The current ratio has decreased by 39% YoY but it has increased by 6% from the previous quarter
Iovance Biotherapeutics's debt is 83% less than its equity
IOVA's debt to equity has soared by 143% YoY and by 21% from the previous quarter
Iovance Biotherapeutics's debt has soared by 54% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.